# Aaron D. Schimmer

Source: https://onco.cc/people/aaron-schimmer/  
OnCo record `aaron-schimmer` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leukaemia researcher who found that AML stem cells depend on mitochondrial proteases and metabolism.

## Summary

Aaron D. Schimmer is Research Director and Senior Scientist at the Princess Margaret Cancer Centre, with an affiliation at the Ontario Institute for Cancer Research. He is a leukaemia researcher who found that acute myeloid leukaemia stem cells depend on mitochondrial proteases such as ClpP and on oxidative phosphorylation. That work led him into drug repurposing, including trials of the antibiotic tigecycline, and his selected paper describes inhibiting mitochondrial translation as a therapeutic strategy in AML. He now directs the research programme at Princess Margaret while continuing to study mitochondrial metabolism in leukaemia.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Research Director, Princess Margaret Cancer Centre; Senior Scientist
- Specialisms: AML; Mitochondrial metabolism; Drug repurposing

## Sources

- UHN profile: https://www.uhnresearch.ca/researcher/aaron-d-schimmer
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Schimmer%20AD%5BAuthor%5D

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- institutions: [Ontario Institute for Cancer Research](https://onco.cc/institutions/oicr/), [Princess Margaret Cancer Centre](https://onco.cc/institutions/princess-margaret/)
- journals: [Cancer Cell](https://onco.cc/journals/cancer-cell/)

---
JSON: https://onco.cc/api/v1/entities/aaron-schimmer.json